{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:31:11Z","timestamp":1770647471630,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00520-020-05484-z","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T10:02:46Z","timestamp":1587981766000},"page":"213-222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4884-6737","authenticated-orcid":false,"given":"Shannon D.","family":"Armbruster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1810-5762","authenticated-orcid":false,"given":"Bryan M.","family":"Fellman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0697-1815","authenticated-orcid":false,"given":"Anuja","family":"Jhingran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9209-7457","authenticated-orcid":false,"given":"Patricia J.","family":"Eifel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2081-0735","authenticated-orcid":false,"given":"Ann H.","family":"Klopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-8754","authenticated-orcid":false,"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5699-9288","authenticated-orcid":false,"given":"Lois M.","family":"Ramondetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-2648","authenticated-orcid":false,"given":"Michael","family":"Frumovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"issue":"6","key":"5484_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"5484_CR2","unstructured":"Network NCC Cervical Cancer (Version 3.2019). https:\/\/jnccn.org\/abstract\/journals\/jnccn\/17\/1\/article-p64.xml. Accessed March 31,2019"},{"issue":"15","key":"5484_CR3","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/nejm199904153401503","volume":"340","author":"HM Keys","year":"1999","unstructured":"Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL, Gersell D (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340(15):1154\u20131161. https:\/\/doi.org\/10.1056\/nejm199904153401503","journal-title":"N Engl J Med"},{"issue":"15","key":"5484_CR4","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1056\/nejm199904153401502","volume":"340","author":"PG Rose","year":"1999","unstructured":"Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340(15):1144\u20131153. https:\/\/doi.org\/10.1056\/nejm199904153401502","journal-title":"N Engl J Med"},{"issue":"15","key":"5484_CR5","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1056\/nejm199904153401501","volume":"340","author":"M Morris","year":"1999","unstructured":"Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340(15):1137\u20131143. https:\/\/doi.org\/10.1056\/nejm199904153401501","journal-title":"N Engl J Med"},{"issue":"1","key":"5484_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1525-1438.2007.00960.x","volume":"18","author":"T Uno","year":"2008","unstructured":"Uno T, Mitsuhashi A, Isobe K, Yamamoto S, Kawakami H, Ueno N, Usui H, Tate S, Kawata T, Ito H (2008) Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix. Int J Gynecol Cancer 18(1):80\u201384. https:\/\/doi.org\/10.1111\/j.1525-1438.2007.00960.x","journal-title":"Int J Gynecol Cancer"},{"key":"5484_CR7","unstructured":"NCCN (2020) National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Antiemetics. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"issue":"2","key":"5484_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2165\/00003495-199855020-00002","volume":"55","author":"RE Gregory","year":"1998","unstructured":"Gregory RE, Ettinger DS (1998) 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. Drugs 55(2):173\u2013189. https:\/\/doi.org\/10.2165\/00003495-199855020-00002","journal-title":"Drugs"},{"key":"5484_CR9","volume-title":"Cancer facts & figures 2019","author":"Society AC","year":"2019","unstructured":"Society AC (2019) Cancer facts & figures 2019. American Cancer Society, Atlanta"},{"key":"5484_CR10","doi-asserted-by":"publisher","unstructured":"Lindley CM, Bernard S, Fields SM (1989) Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. 7. https:\/\/doi.org\/10.1200\/JCO.1989.7.8.1142","DOI":"10.1200\/JCO.1989.7.8.1142"},{"issue":"16","key":"5484_CR11","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.12968\/bjon.2016.25.S4","volume":"25","author":"C Vidall","year":"2016","unstructured":"Vidall C, Sharma S, Amlani B (2016) Patient-practitioner perception gap in treatment-induced nausea and vomiting. Br J Nurs 25(16):S4\u2013s11. https:\/\/doi.org\/10.12968\/bjon.2016.25.S4","journal-title":"Br J Nurs"},{"issue":"11","key":"5484_CR12","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1007\/s00520-015-2750-5","volume":"23","author":"C Vidall","year":"2015","unstructured":"Vidall C, Fern\u00e1ndez-Ortega P, Cortinovis D, Jahn P, Amlani B, Scott\u00e9 F (2015) Impact and management of chemotherapy\/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists\/oncology nurses and patients: a cross-sectional multinational survey. Support Care Cancer 23(11):3297\u20133305. https:\/\/doi.org\/10.1007\/s00520-015-2750-5","journal-title":"Support Care Cancer"},{"key":"5484_CR13","doi-asserted-by":"publisher","unstructured":"Gregor MC-M, He W, Zhao H, Elting LS, Giordano SH (2015) Antiemesis prophylaxis among breast cancer (BC) patients receiving highly emetogenic chemotherapy. 33(15_suppl):e12005. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.e12005","DOI":"10.1200\/jco.2015.33.15_suppl.e12005"},{"key":"5484_CR14","doi-asserted-by":"publisher","unstructured":"Smith J, Anastasia P, Rappaport M (2012) Prevention and treatment of chemotherapy-induced nausea and vomiting with the granisetron transdermal system (GTDS): three clinical perspectives on three case studies in solid tumors. 10. https:\/\/doi.org\/10.1016\/j.suponc.2012.07.001","DOI":"10.1016\/j.suponc.2012.07.001"},{"issue":"4","key":"5484_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/1078155209104063","volume":"15","author":"J Howell","year":"2009","unstructured":"Howell J, Smeets J, Drenth HJ, Gill D (2009) Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract 15(4):223\u2013231. https:\/\/doi.org\/10.1177\/1078155209104063","journal-title":"J Oncol Pharm Pract"},{"key":"5484_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4137\/CMT.S10240","volume":"8","author":"H Kitayama","year":"2016","unstructured":"Kitayama H (2016) Granisetron transdermal system in the management of chemotherapy-induced nausea and vomiting. Clin Med Insights 8:37\u201344. https:\/\/doi.org\/10.4137\/CMT.S10240","journal-title":"Clin Med Insights"},{"issue":"6","key":"5484_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.21037\/cco.2016.12.04","volume":"5","author":"LQ Yang","year":"2016","unstructured":"Yang LQ, Sun XC, Qin SK, Chen YX, Zhang HL, Cheng Y, Chen ZD, Shi JH, Wu Q, Bai YX, Han BH, Liu W, Ouyang XN, Liu JW, Zhang ZH, Li YQ, Xu JM, Yu SY (2016) Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study. Chin Clin Oncol 5(6):79. https:\/\/doi.org\/10.21037\/cco.2016.12.04","journal-title":"Chin Clin Oncol"},{"issue":"10","key":"5484_CR18","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s00520-010-0990-y","volume":"19","author":"RV Boccia","year":"2011","unstructured":"Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM (2011) Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 19(10):1609\u20131617. https:\/\/doi.org\/10.1007\/s00520-010-0990-y","journal-title":"Support Care Cancer"},{"issue":"3","key":"5484_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/sim.4780140302","volume":"14","author":"DA Berry","year":"1995","unstructured":"Berry DA, Eick SG (1995) Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat Med 14(3):231\u2013246","journal-title":"Stat Med"},{"key":"5484_CR20","unstructured":"Network NCC (2020) NCCN Clinical Practice Guidelines in Oncology: Antiemetics"},{"issue":"3","key":"5484_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/cncr.11540","volume":"98","author":"CG Martin","year":"2003","unstructured":"Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D (2003) Measuring chemotherapy-induced nausea and emesis. Cancer 98(3):645\u2013655. https:\/\/doi.org\/10.1002\/cncr.11540","journal-title":"Cancer"},{"issue":"1","key":"5484_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","volume":"24","author":"DE Morisky","year":"1986","unstructured":"Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24(1):67\u201374","journal-title":"Med Care"},{"issue":"5","key":"5484_CR23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","volume":"10","author":"DE Morisky","year":"2008","unstructured":"Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 10(5):348\u2013354","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"28","key":"5484_CR24","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 35(28):3240\u20133261. https:\/\/doi.org\/10.1200\/JCO.2017.74.4789","journal-title":"J Clin Oncol"},{"issue":"1","key":"5484_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","volume":"25","author":"J Herrstedt","year":"2017","unstructured":"Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, Chan A, Aapro MS (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer 25(1):277\u2013288. https:\/\/doi.org\/10.1007\/s00520-016-3313-0","journal-title":"Support Care Cancer"},{"issue":"1","key":"5484_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E, Jerzak KJ (2019) ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27(1):87\u201395. https:\/\/doi.org\/10.1007\/s00520-018-4464-y","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05484-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05484-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05484-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:22:43Z","timestamp":1619482963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05484-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5484"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05484-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]},"assertion":[{"value":"18 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Frumovitz reports personal fees from Genetech, personal fees from Ipsen, grants, personal fees, and non-financial support from Stryker, outside the submitted work. No other conflicts exist for other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (IRB, 2011-1107) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}